25 years of lipid-lowering therapy: secular trends in therapy of coronary patients
Wiener klinische Wochenschrift · 2025
DOI: 10.1007/s00508-024-02365-x ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Wiener klinische Wochenschrift, 2025. Verfasst von Magdalena Ratz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Private University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein. Hauptthemen laut MEDLINE: Hypolipidemic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Practice Patterns, Physicians', Coronary Artery Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIM: Guidelines on dyslipidemia and lipid-lowering therapy (LLT) over the years recommend lower low-density lipoprotein cholesterol (LDL-C) goals by more intense therapy. Nevertheless, LDL‑C has increased in the general population. Real-world trends of LLT medication as well as of LDL‑C levels in cardiovascular high-risk patients are unclear. METHODS: From 2158 patients who were referred for elective coronary angiography, lipid medication was analyzed at admission in three cardiovascular observational studies (OS) over the last 25 years: OS1: 1999-2000, OS2: 2005-2008 and OS3: 2022-2023. The three studies were performed at the same cardiology unit of a tertiary care hospital in Austria. RESULTS: The proportion of patients without LLT significantly decreased from OS1 through OS2 to OS3 (49.4%, 45.6%, and 18.5%, respectively, ptrend < 0.001). Moreover, the percentage of patients under high-intensity statin treatment significantly increased from 0% to 5.1%, and 56.5% (ptrend < 0.001). Significantly more patients became treated by more than one compound (OS1: 1.8%, OS2: 1.6%, OS3: 31.2%; ptrend < 0.001). In the latest OS3, a trend to fixed-dose combination of statins with ezetimibe was observed. Mean LDL‑C levels decreased from 129 mg/dL over 127 mg/dL to 83 mg/dL, respectively (ptrend < 0.001). Of the patients on high-intensity therapy 34% met the recent ESC/EAS goals (LDL-C < 55 mg/dL), but only 3% on non-intense therapy. CONCLUSION: We conclude that during the observational period of a quarter of a century, treatment intensity increased and LDL‑C levels improved considerably. Guidelines apparently matter in this high-risk population and are considered by primary care physicians.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Private University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein.
- Vorarlberg Institute for Vascular Investigation & Treatment, (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria.
- Department of Internal Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
- Central Medical Laboratories, Feldkirch, Austria.
- Private University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein. andreas.leiherer@vivit.at.
- Vorarlberg Institute for Vascular Investigation & Treatment, (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria. andreas.leiherer@vivit.at.
Zitieren
APA
Ratz, M., Vogel, J. B., Kührer, H., Säly, C. H., Mündlein, A., Vonbank, A., Mader, A., Fraunberger, P., Leiherer, A., & Drexel, H. (2025). 25 years of lipid-lowering therapy: secular trends in therapy of coronary patients. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-024-02365-x
Vancouver
Ratz M, Vogel JB, Kührer H, Säly CH, Mündlein A, Vonbank A, et al. 25 years of lipid-lowering therapy: secular trends in therapy of coronary patients. Wiener klinische Wochenschrift. 2025. doi:10.1007/s00508-024-02365-x
BibTeX
@article{Ratz2025,
author = {Ratz, Magdalena and Vogel, Johannes B and Kührer, Heike and Säly, Christoph H and Mündlein, Axel and Vonbank, Alexander and Mader, Arthur and Fraunberger, Peter and Leiherer, Andreas and Drexel, Heinz},
title = {25 years of lipid-lowering therapy: secular trends in therapy of coronary patients},
journal = {Wiener klinische Wochenschrift},
year = {2025},
doi = {10.1007/s00508-024-02365-x}
}
EUVIMED